Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · IEX Real-Time Price · USD
114.97
+1.51 (1.33%)
At close: Jul 19, 2024, 4:00 PM
114.91
-0.06 (-0.05%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Blueprint Medicines Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for Blueprint Medicines stock have an average target of 116.33, with a low estimate of 75 and a high estimate of 168. The average target predicts an increase of 1.18% from the current stock price of 114.97.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BPMC stock from 15 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 5 | 5 |
| Buy | 4 | 4 | 5 | 6 | 5 | 5 |
| Hold | 3 | 3 | 2 | 4 | 4 | 4 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 15 | 15 | 15 | 17 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $110 → $115 | Hold | Maintains | $110 → $115 | +0.03% | Jul 12, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $114 → $125 | Buy | Maintains | $114 → $125 | +8.72% | Jul 8, 2024 |
| Needham | Needham | Strong Buy Reiterates $130 | Strong Buy | Reiterates | $130 | +13.07% | Jun 28, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $125 | Buy | Reiterates | $125 | +8.72% | Jun 7, 2024 |
| Stephens & Co. | Stephens & Co. | Buy Initiates $140 | Buy | Initiates | $140 | +21.77% | May 14, 2024 |
Financial Forecast
Revenue This Year
438.15M
from 249.38M
Increased by 75.70%
Revenue Next Year
661.12M
from 438.15M
Increased by 50.89%
EPS This Year
-2.38
from -8.37
EPS Next Year
-1.57
from -2.38
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 519.8M | 1.0B | 1.2B | 1.5B | 1.9B |
| Avg | 438.2M | 661.1M | 906.3M | 1.2B | 1.3B |
| Low | 392.0M | 540.0M | 733.0M | 889.9M | 996.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 108.4% | 131.0% | 81.8% | 66.3% | 57.9% |
| Avg | 75.7% | 50.9% | 37.1% | 29.3% | 12.8% |
| Low | 57.2% | 23.2% | 10.9% | -1.8% | -14.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.16 | 1.80 | 6.16 | 5.39 | 7.71 |
| Avg | -2.38 | -1.57 | 1.48 | 4.70 | 7.49 |
| Low | -3.88 | -3.90 | -2.43 | 4.00 | 7.19 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 263.1% | 64.1% |
| Avg | - | - | - | 216.7% | 59.4% |
| Low | - | - | - | 169.6% | 53.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.